Founded in 2021, RinuaGene is dedicated to developing innovative RNA therapeutics and vaccines to address critical health challenges around the world.

With a strong foundation in scientific expertise, pharmaceutical industry experience, and managerial excellence, RinuaGene is efficiently advancing its FIC/BIC product pipeline and strengthening its cutting-edge technological platform.

Driven by innovation, RinuaGene is committed to establishing a world-class platform for RNA-based drugs and vaccines. Our goal is to deliver high-quality, transformative solutions that improve human health and contribute to a healthier future worldwide.